Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onterodrimer
- Development stage
- Unknown
- Lead developer
- Kaleido Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Onterodrimer** (formerly KB-195) is a targeted glycan **microbiome metabolic therapeutic (MMT)**, a type of **chemical drug** designed to modulate the gut microbiome for therapeutic benefit. Developed by **Kaleido Biosciences**, it targets **hyperammonemia**, a condition characterized by elevated ammonia levels often associated with urea cycle disorders. Its mechanism involves altering microbiome composition to influence metabolic pathways, potentially reducing ammonia production or enhancing its clearance. Development reached **Phase 2** trials in the United Kingdom (started 17 Sep 2019) and Switzerland (started 31 Dec 2018), but the program appears **discontinued**, with no evidence of further advancement or approval.[3][7][9]
- Other names
- gluco-oligosaccharide mixture
Beyond the preview
Go deeper on onterodrimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onterodrimer.